Cargando…

The effects of oclacitinib treatment on antimicrobial usage in allergic dogs in primary practice: an Australia wide case-control study

BACKGROUND: Canine allergic dermatitis is a common diagnosis in veterinary practices which can lead to secondary infections requiring treatment with antimicrobials. A previous study suggested that dogs treated with oclacitinib in an Australian referral hospital required fewer courses of antimicrobia...

Descripción completa

Detalles Bibliográficos
Autores principales: Rynhoud, Hester, Croton, Catriona, Henry, Grace, Meler, Erika, Gibson, Justine S., Soares Magalhaes, Ricardo J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044603/
https://www.ncbi.nlm.nih.gov/pubmed/35477466
http://dx.doi.org/10.1186/s12917-022-03255-y
_version_ 1784695140166664192
author Rynhoud, Hester
Croton, Catriona
Henry, Grace
Meler, Erika
Gibson, Justine S.
Soares Magalhaes, Ricardo J.
author_facet Rynhoud, Hester
Croton, Catriona
Henry, Grace
Meler, Erika
Gibson, Justine S.
Soares Magalhaes, Ricardo J.
author_sort Rynhoud, Hester
collection PubMed
description BACKGROUND: Canine allergic dermatitis is a common diagnosis in veterinary practices which can lead to secondary infections requiring treatment with antimicrobials. A previous study suggested that dogs treated with oclacitinib in an Australian referral hospital required fewer courses of antimicrobial therapy compared to dogs receiving other anti-pruritic treatments. This study aimed to quantify the effect of oclacitinib treatment on the use of antimicrobials and other therapies in general practice veterinary clinics across Australia. A retrospective case-controlled review of patient records was designed to investigate the number of courses of antimicrobials and other therapies in dogs that received oclacitinib (Apoquel®), compared with those who received an anti-pruritic treatment that was not oclacitinib. RESULTS: The target population included canine patients with a presumptive diagnosis of allergic dermatitis presenting between 2008 and 2018 to general practices contributing to the VetCompass Australia database. Patient records of interest were identified using search terms relating to allergic dermatitis, resulting in over 700,000 observations. Multivariable logistic regression models were developed to determine whether cases were prescribed fewer antimicrobial courses than controls, after adjusting for the presence of concurrent skin infections or infectious agents in ears. Our results indicate that fewer antimicrobial courses were prescribed in the cases compared to the controls. After adjusting for the concurrent skin infections, there was a significant reduction in the use of cefovecin [OR:0.62(0.39–0.98), P = 0.043], chlorhexidine [OR:0.57(0.42–0.77), P < 0.001], neomycin [OR:0.4(0.28–0.56), P < 0.001] and amoxycillin clavulanic acid (AMC) [OR: 0.55(0.39–0.78), P = 0.001] in cases compared to controls. CONCLUSION: This study demonstrates a potential sparing effect of oclacitinib on the prescription of antimicrobials for the treatment of allergic skin diseases in dogs. This information may assist in the planning of treatment for canine allergic dermatitis, with consideration for antimicrobial stewardship. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12917-022-03255-y.
format Online
Article
Text
id pubmed-9044603
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-90446032022-04-28 The effects of oclacitinib treatment on antimicrobial usage in allergic dogs in primary practice: an Australia wide case-control study Rynhoud, Hester Croton, Catriona Henry, Grace Meler, Erika Gibson, Justine S. Soares Magalhaes, Ricardo J. BMC Vet Res Research BACKGROUND: Canine allergic dermatitis is a common diagnosis in veterinary practices which can lead to secondary infections requiring treatment with antimicrobials. A previous study suggested that dogs treated with oclacitinib in an Australian referral hospital required fewer courses of antimicrobial therapy compared to dogs receiving other anti-pruritic treatments. This study aimed to quantify the effect of oclacitinib treatment on the use of antimicrobials and other therapies in general practice veterinary clinics across Australia. A retrospective case-controlled review of patient records was designed to investigate the number of courses of antimicrobials and other therapies in dogs that received oclacitinib (Apoquel®), compared with those who received an anti-pruritic treatment that was not oclacitinib. RESULTS: The target population included canine patients with a presumptive diagnosis of allergic dermatitis presenting between 2008 and 2018 to general practices contributing to the VetCompass Australia database. Patient records of interest were identified using search terms relating to allergic dermatitis, resulting in over 700,000 observations. Multivariable logistic regression models were developed to determine whether cases were prescribed fewer antimicrobial courses than controls, after adjusting for the presence of concurrent skin infections or infectious agents in ears. Our results indicate that fewer antimicrobial courses were prescribed in the cases compared to the controls. After adjusting for the concurrent skin infections, there was a significant reduction in the use of cefovecin [OR:0.62(0.39–0.98), P = 0.043], chlorhexidine [OR:0.57(0.42–0.77), P < 0.001], neomycin [OR:0.4(0.28–0.56), P < 0.001] and amoxycillin clavulanic acid (AMC) [OR: 0.55(0.39–0.78), P = 0.001] in cases compared to controls. CONCLUSION: This study demonstrates a potential sparing effect of oclacitinib on the prescription of antimicrobials for the treatment of allergic skin diseases in dogs. This information may assist in the planning of treatment for canine allergic dermatitis, with consideration for antimicrobial stewardship. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12917-022-03255-y. BioMed Central 2022-04-27 /pmc/articles/PMC9044603/ /pubmed/35477466 http://dx.doi.org/10.1186/s12917-022-03255-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Rynhoud, Hester
Croton, Catriona
Henry, Grace
Meler, Erika
Gibson, Justine S.
Soares Magalhaes, Ricardo J.
The effects of oclacitinib treatment on antimicrobial usage in allergic dogs in primary practice: an Australia wide case-control study
title The effects of oclacitinib treatment on antimicrobial usage in allergic dogs in primary practice: an Australia wide case-control study
title_full The effects of oclacitinib treatment on antimicrobial usage in allergic dogs in primary practice: an Australia wide case-control study
title_fullStr The effects of oclacitinib treatment on antimicrobial usage in allergic dogs in primary practice: an Australia wide case-control study
title_full_unstemmed The effects of oclacitinib treatment on antimicrobial usage in allergic dogs in primary practice: an Australia wide case-control study
title_short The effects of oclacitinib treatment on antimicrobial usage in allergic dogs in primary practice: an Australia wide case-control study
title_sort effects of oclacitinib treatment on antimicrobial usage in allergic dogs in primary practice: an australia wide case-control study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9044603/
https://www.ncbi.nlm.nih.gov/pubmed/35477466
http://dx.doi.org/10.1186/s12917-022-03255-y
work_keys_str_mv AT rynhoudhester theeffectsofoclacitinibtreatmentonantimicrobialusageinallergicdogsinprimarypracticeanaustraliawidecasecontrolstudy
AT crotoncatriona theeffectsofoclacitinibtreatmentonantimicrobialusageinallergicdogsinprimarypracticeanaustraliawidecasecontrolstudy
AT henrygrace theeffectsofoclacitinibtreatmentonantimicrobialusageinallergicdogsinprimarypracticeanaustraliawidecasecontrolstudy
AT melererika theeffectsofoclacitinibtreatmentonantimicrobialusageinallergicdogsinprimarypracticeanaustraliawidecasecontrolstudy
AT gibsonjustines theeffectsofoclacitinibtreatmentonantimicrobialusageinallergicdogsinprimarypracticeanaustraliawidecasecontrolstudy
AT soaresmagalhaesricardoj theeffectsofoclacitinibtreatmentonantimicrobialusageinallergicdogsinprimarypracticeanaustraliawidecasecontrolstudy
AT rynhoudhester effectsofoclacitinibtreatmentonantimicrobialusageinallergicdogsinprimarypracticeanaustraliawidecasecontrolstudy
AT crotoncatriona effectsofoclacitinibtreatmentonantimicrobialusageinallergicdogsinprimarypracticeanaustraliawidecasecontrolstudy
AT henrygrace effectsofoclacitinibtreatmentonantimicrobialusageinallergicdogsinprimarypracticeanaustraliawidecasecontrolstudy
AT melererika effectsofoclacitinibtreatmentonantimicrobialusageinallergicdogsinprimarypracticeanaustraliawidecasecontrolstudy
AT gibsonjustines effectsofoclacitinibtreatmentonantimicrobialusageinallergicdogsinprimarypracticeanaustraliawidecasecontrolstudy
AT soaresmagalhaesricardoj effectsofoclacitinibtreatmentonantimicrobialusageinallergicdogsinprimarypracticeanaustraliawidecasecontrolstudy